Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) EBITDA Margin: 2012-2025

Historic EBITDA Margin for Sunshine Biopharma (SBFM) over the last 12 years, with Sep 2025 value amounting to -15.77%.

  • Sunshine Biopharma's EBITDA Margin fell 1167.00% to -15.77% in Q3 2025 from the same period last year, while for Sep 2025 it was -17.37%, marking a year-over-year decrease of 444.00%. This contributed to the annual value of -19.10% for FY2024, which is 261.00% down from last year.
  • Sunshine Biopharma's EBITDA Margin amounted to -15.77% in Q3 2025, which was down 116.29% from -7.29% recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's EBITDA Margin peaked at 824.72% during Q4 2021, and registered a low of -15,445.58% during Q1 2021.
  • Moreover, its 3-year median value for EBITDA Margin was -14.29% (2024), whereas its average is -16.55%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 1,458,447bps in 2021, then skyrocketed by 1,443,842bps in 2022.
  • Over the past 5 years, Sunshine Biopharma's EBITDA Margin (Quarterly) stood at 824.72% in 2021, then plummeted by 141,537bps to -590.65% in 2022, then soared by 58,077bps to -9.88% in 2023, then crashed by 2,302bps to -32.90% in 2024, then tumbled by 1,167bps to -15.77% in 2025.
  • Its EBITDA Margin was -15.77% in Q3 2025, compared to -7.29% in Q2 2025 and -12.96% in Q1 2025.